{"nctId":"NCT01001494","briefTitle":"Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients","startDateStruct":{"date":"2009-10"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":828,"armGroups":[{"label":"Aclidinium bromide 200 μg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide 200 μg bid"]},{"label":"Aclidininum bromide 400 μg bid","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium bromide 400 μg bid"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclidinium bromide 200 μg bid","otherNames":[]},{"name":"Aclidinium bromide 400 μg bid","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult male and female patients aged ≥40 with stable moderate to severe COPD (GOLD guidelines).\n* Post-salbutamol (FEV1) \\< 80% and ≥30% of predicted normal value and Post-salbutamol FEV1/FVC \\< 70%.\n* Current or ex-smokers of ≥10 pack-years.\n\nExclusion Criteria:\n\n* Patients with no history or current diagnosis of asthma.\n* No evidence of an exacerbation within 6 weeks prior to the screening visit.\n* No evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.\n* No contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.026","spread":"0.016"},{"groupId":"OG001","value":"0.055","spread":"0.016"},{"groupId":"OG002","value":"-0.073","spread":"0.016"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in the First Second (FEV1) at Week 12 on Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.030","spread":"0.014"},{"groupId":"OG001","value":"0.058","spread":"0.015"},{"groupId":"OG002","value":"-0.047","spread":"0.015"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Peak Forced Expiratory Volume in the First Second (FEV1) at Week 24 on Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.206","spread":"0.017"},{"groupId":"OG001","value":"0.231","spread":"0.017"},{"groupId":"OG002","value":"0.022","spread":"0.017"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved at Least a 1-unit Decrease From Baseline in TDI Focal Score at Week 24 on Treatment","description":"Number of patients achieving a clinically meaningful improvement (≥1-unit) in Transition Dyspnoea Index (TDI) focal score at Week 24 on Treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null},{"groupId":"OG001","value":"56.9","spread":null},{"groupId":"OG002","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"43.1","spread":null},{"groupId":"OG002","value":"54.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Who Achieved at Least a 4-unit Decrease From Baseline in the SGRQ Total Score at Week 24 on Treatment","description":"Number of patients who achieved a clinically meaningful improvement (≥4-units) in Saint George Respiratory Questionnaire (SGRQ) total score at week 24 on treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"57.3","spread":null},{"groupId":"OG002","value":"41.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":null},{"groupId":"OG001","value":"42.8","spread":null},{"groupId":"OG002","value":"59.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":277},"commonTop":["Chronic obstructivce pulmonary disease","Headache","Nasopharyngitis"]}}}